These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 28366429)
21. California cracks down on stem cell cowboys. DeFrancesco L Nat Biotechnol; 2017 Dec; 35(12):1119. PubMed ID: 29220025 [No Abstract] [Full Text] [Related]
22. To market, to market. The nuts and bolts of prescription drug approval. Peterson AM Adv Nurse Pract; 2001 Apr; 9(4):87-90. PubMed ID: 12420443 [No Abstract] [Full Text] [Related]
23. Pharmaceuticals and medical devices: FDA oversight. Berry MD Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893 [No Abstract] [Full Text] [Related]
27. Drug marketing exclusivity under United States and European Union law. Junod V Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347 [No Abstract] [Full Text] [Related]
28. Changes at FDA may speed drug approval process and increase off-label use. Reh M J Natl Cancer Inst; 1998 Jun; 90(11):805-7. PubMed ID: 9625166 [No Abstract] [Full Text] [Related]
29. Challenges in the Regulation of Autologous Stem Cell Interventions in the United States. Sipp D Perspect Biol Med; 2018; 61(1):25-41. PubMed ID: 29805146 [TBL] [Abstract][Full Text] [Related]
30. Regulatory aspects of drug approval for macular degeneration. Gryziewicz L Adv Drug Deliv Rev; 2005 Dec; 57(14):2092-8. PubMed ID: 16316706 [TBL] [Abstract][Full Text] [Related]
31. Progress and deficiencies in the registration of clinical trials. Wood AJ N Engl J Med; 2009 Feb; 360(8):824-30. PubMed ID: 19228628 [No Abstract] [Full Text] [Related]
32. The problem of new uses. Eisenberg RS Yale J Health Policy Law Ethics; 2005; 5(2):717-39. PubMed ID: 16052897 [No Abstract] [Full Text] [Related]
33. Stem-cell-derived products: an FDA update. Moos M Trends Pharmacol Sci; 2008 Dec; 29(12):591-3. PubMed ID: 18937983 [TBL] [Abstract][Full Text] [Related]
34. Stem cell transplantation in India: tall claims, questionable ethics. Pandya SK Indian J Med Ethics; 2008; 5(1):15-7. PubMed ID: 18630246 [No Abstract] [Full Text] [Related]
35. Lessons for reviewing clinical trials using induced pluripotent stem cells: examining the case of a first-in-human trial for age-related macular degeneration. Takashima K; Inoue Y; Tashiro S; Muto K Regen Med; 2018 Mar; 13(2):123-128. PubMed ID: 29210321 [No Abstract] [Full Text] [Related]